| |
Course Number |
Course Title |
Guest |
|
| |
15.928 |
Strategic Management and Consulting: Current Strategic Challenges for Global Enterprises |
Daniel Vasella
CEO, Novartis |
|
| |
RF.449 |
SIP: Healthcare in Turmoil |
Frank Douglas
Former CSO, Aventis |
|
| |
RF.402 |
SIP: Organizational Economics |
Judy Lewent
CFO, Merck & Co. |
|
| |
15.966 |
Managing in Adversity |
Jim Foster
CEO, Charles River Laboratories |
|
| |
15.966 |
Managing in Adversity |
Paul Levy
CEO, Beth Israel Hospital |
|
| |
15.966 |
Managing in Adversity |
Gabe Schmergel
Former CEO, Genetics Institute |
|
| |
15.398 |
NPVD Proseminar: Entrepreneurs in Innovation: IT, Energy, Biotechnology & Communications |
Richard Pops
CEO, Alkermes |
|
| |
15.398 |
NPVD Proseminar: Entrepreneurs in Innovation: IT, Energy, Biotechnology & Communications |
Jim Tobin
CEO, Boston Scientific |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Thomas Finneran
President, Massachusetts Biotechnology Council
Former Speaker of the House, Massachusetts State Legislature |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Una Ryan
CEO, Avant Immunotherapeutics
Chair, Massachusetts Biotechnology Council |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Ted Llana
Senior Vice President, Corporate Strategy, Biogen Idec |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Nicholas Franco
Global Head, BD&L, Novartis Pharma AG |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Jerry Avorn
Professor, Harvard Medical School |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Nancy Ostrove
Director for Risk Communications, US FDA |
|
| |
15.141J/HST.918J |
Economics of Healthcare Industries |
Owen Barder
Senior Program Associate, Center for Global Development
Former Economic Affairs Private Secretary to Tony Blair |
|